Special Issue

Discovery of Antibody Biomarker

Message from the Guest Editor

Biomarkers are important and indispensable not only for diagnosis but also for the identification of therapeutic targets. Autoantibodies have causal roles in autoimmune diseases, and may affect the development of cancer. The recent development of technology has revealed that autoantibodies are developed against most proteins in the body. Such autoantibodies may reflect an individual's medical history. Therefore, autoantibodies can be applicable for diagnosis of other varieties of diseases in addition to autoimmune disease and cancer. Antibody levels are tremendously increased by repeated exposure to

antigens. Therefore, antibody markers are highly sensitive and capable of discriminate trivial alterations of cells and organs. It has been suggested that autoantibodies sometimes play causal roles in other diseases than autoimmune diseases. Thus, analysis of autoantibodies is effective in the identification of therapeutic targets. Remarkable development of antibody biomarkers is expected in the future.

Guest Editor

Dr. Takaki Hiwasa

Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan

Deadline for manuscript submissions

closed (31 December 2019)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/34007

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

